GeNeuro SA is a Swiss-based clinical-stage biopharmaceutical company specializing in the development of monoclonal antibodies to neutralize pathogenic proteins from human endogenous retroviruses (HERVs) implicated in neurodegenerative and autoimmune diseases. Its lead candidate, temelimab, targets the HERV-W Env protein and has completed Phase II trials in multiple sclerosis, demonstrating impacts on key MRI markers of disease progression, while also advancing in Phase II for post-COVID neuropsychiatric syndromes with Swiss government funding. Additional programs include GNC-501 for persistent post-COVID effects and GNK301 for sporadic amyotrophic lateral sclerosis in preclinical stages. GeNeuro SA collaborates with institutions like the National Institute of Neurological Disorders and Stroke, FondaMental Foundation, and Northwestern University to explore HERV proteins in conditions such as ALS and long-COVID. Founded in 2006 and headquartered in Plan-les-Ouates, Switzerland, the company plays a pivotal role in addressing unmet needs in neurology by targeting underlying causal factors rather than symptoms alone.